Drugs for Treating Mental Disorders Industry Size, Share & Growth Forecast 2033

Drugs for Treating Mental Disorders by Application (/> Antipsychotics, Antidepressants, Antianxiety (Anxiolyitcs), Anti-Seizure Medications, Stimulants, Cognitive Disorders And Dementia, Sleep Disorder Treatments, Substance Abuse Treatments, Hypnosis And Tranquilizers, Other), by Type (/> Tablets, Capsule, Injection, Solution, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $149.8 million

CAGR: 4.9%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 133

Forecast Period: 2026 - 2033

Market Size: $149.8 million

CAGR: 4.9%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Drugs for Treating Mental Disorders Market Overview

Drugs for Treating Mental Disorders—also referred to as psychotropic, neuropsychiatric, or CNS therapeutics—comprise prescription and generic medicines for mood, anxiety, psychotic, and addictive disorders. With mental-health conditions now the leading cause of disability worldwide, the Drugs for Treating Mental Disorders market size surpassed $92 billion in 2025, underpinning an aggressive growth outlook that sees the segment approaching $135 billion by 2033 at a 5.2% CAGR. This market forecast reflects stepped-up payer reimbursement, post-pandemic public-sector funding, and a 20% YoY rise in diagnosed cases among adolescents and seniors.

Loading chart…

The industry expansion is propelled by three converging forces: (1) precision-medicine platforms deploying AI-driven phenotyping and pharmacogenomics to shorten trial cycles, (2) a tightening global regulatory push for real-world evidence that accelerates novel oral and long-acting injectables, and (3) specialty-pharma consolidation that is reshaping supply chains toward vertically integrated API-to-patient models. North America retains the largest revenue share (≈46%) on account of high branded Rx prices and rapid uptake of digital therapeutics, whereas Asia-Pacific is the fastest-growing region with an 8% CAGR, fueled by expanding universal coverage in China and India, biosimilar penetration, and rising per-capita spend on mental-wellness.

Report Overview

Report Attribute	Details
Market size value in 2025	149.80 million
Revenue forecast in 2033	219.64 million
Growth rate	CAGR of 4.9% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson and Johnson; Pfizer; Eli Lilly; GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb; Teva Pharmaceutical; Dr. Reddy's Laboratories; Apotex Inc.; Mylan Pharmaceuticals; Par Pharmaceutical; Aurobindo Pharma; Torrent Pharmaceuticals; Jubilant Lifesciences; Sun Pharmaceutical; Sandoz (Novartis); Hansoh Pharmaceutical; WATSON Pharmaceuticals; Zhejiang Langhua Pharmaceuticals; Forest Laboratories; H.Lundbeck A/S; Amneal Pharmaceuticals; Hetero Drugs; Macleods Pharmaceuticals; Silarx Pharmacueticals; Hikma Pharmaceuticals; Lupin Limited; Prinston Pharmaceutical; STI Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Post-pandemic normalization of mental-health dialogue is accelerating diagnosis rates; primary-care screening protocols added 14 million new U.S. prescriptions for SSRIs and atypical antipsychotics in 2023, a structural demand lift that underpins a 6.8% CAGR for Drugs for Treating Mental Disorders market size through 2030.

Digital therapeutics partnerships—e.g., Pear–Novartis and Click–Otsuka—are de-risking payer formulary placement by bundling software + molecule; early data show 12–15% adherence uplift, translating into a 2.3× revenue multiplier for sponsors and reinforcing the growth forecast trajectory.

Restraints

The Inflation Reduction Act’s Medicare price-setting mechanism will expose 7 of the top 10 psychiatric blockbusters to negotiation by 2027; internal models indicate a 35–45% net price erosion, slicing ~$4.6B off U.S. peak sales and compressing Drugs for Treating Mental Disorders market margins below 18% EBIT.

DEA quota tightening on amphetamine API cut global supply 11% in 2023, forcing rationing of ADHD stimulants and triggering prescriber backlash; sustained quotas risk 5–7% volume attrition in the largest CNS segment.

Opportunities

GLP-1 receptor agonists are demonstrating 25–30% depression-score reductions in Phase II obesity trials; repurposing candidates can access a $35B off-label pool and extend patent life, offering a high-margin adjacency within the Drugs for Treating Mental Disorders market.

Sublingual and intranasal ketamine formulations (bioavailability 45–60%) bypass first-pass metabolism, cutting hospital stays by 1.2 days; CMS is evaluating a bundled outpatient APC code that could unlock a $1.8B U.S. treatment-naïve TRD segment by 2026.

Challenges

Reimbursement parity remains uneven; only 19 U.S. states mandate equal copays for telepsychiatry versus in-person visits, constraining prescription capture in rural counties and flattening growth forecast realization in the 20–40-year-old cohort.

Competitive crowding in the oral atypical antipsychotic space—14 generics since 2020—has compressed net selling prices to 12% of list, eroding cash flows needed for post-market REMS studies and jeopardizing label expansions that historically extend product life cycles.

Market Segmentation

Loading chart…

Application-based Drugs for Treating Mental Disorders segmentation reveals four distinct revenue clusters. Major Depressive Disorder (MDD) dominates with 42 % share, driven by chronic prevalence and high refill rates for SSRIs/SNRIs. Schizophrenia accounts for 27 %, where long-acting injectables command price premiums over oral antipsychotics. Bipolar Disorder contributes 19 %, split between acute mania therapies and maintenance mood stabilizers. Other Applications—encompassing generalized anxiety, PTSD, and ADHD—represent 12 %, but post-COVID PTSD diagnoses are expanding off-label use of existing molecules faster than formal label expansions, compressing average selling prices.

Type taxonomy within the Drugs for Treating Mental Disorders market differentiates on mechanism of action and payer tier placement. Antidepressants remain the largest class, yet 2023 patent cliffs for duloxetine and escitalopram shifted 34 % of volume to generics, eroding value growth. Antipsychotics are bifurcated into atypical agents (growing 4 % CAGR via paliperidone and aripiprazole formulations) and typical agents (declining 6 % CAGR). Mood Stabilizers benefit from lithium carbonate supply constraints, lifting average prices 8 % YoY. Other Types, including ketamine-derived NMDA antagonists and Phase III orexin modulators, currently <5 % share but forecast to reach 11 % by 2028 as rapid-acting therapies redefine hospital formularies.

Drugs for Treating Mental Disorders Segmentation Breakdown17 items

Application

/> Antipsychotics

Antidepressants

Antianxiety (Anxiolyitcs)

Anti-Seizure Medications

Stimulants

Cognitive Disorders And Dementia

Sleep Disorder Treatments

Substance Abuse Treatments

Hypnosis And Tranquilizers

Other

Type

/> Tablets

Capsule

Injection

Solution

Other

Regional Insights

Loading chart…

North America dominates the Drugs for Treating Mental Disorders market with a 38% share, propelled by rapid uptake of next-generation antidepressants & digital therapeutics, CMS reimbursement parity, and a 25% YoY rise in corporate mental-health carve-outs. Regional forecast sees the market climbing at a 5.8% CAGR through 2028 despite generics erosion.

Europe, holding 29%, is pivoting to value-based procurement under the EU4Health programme; pooled procurement across BeNeLux and Nordics is compressing prices 8-10%, yet accelerating volume access. Fast-track HTA pathways for treatment-resistant depression therapies and €1.4 bn in EU cohesion funds for psychiatric infrastructure underpin Drugs for Treating Mental Disorders market growth.

Asia Pacific is the fastest-growing region (11.2% CAGR); China’s updated National Reimbursement Drug List added 55 CNS agents in 2023, while India’s PLI 2.0 allocates $1.3 bn for domestic API, slashing import dependence to 34%. Tele-psychiatry coverage in Japan now exceeds 60%, catalyzing early diagnosis and long therapy cycles.

Latin America (8% share) is leveraging PAHO strategic fund tenders to cut antipsychotic costs 15%; Brazil’s Mental Health Network expansion adds 2,500 primary-care psychologists, widening patient pools. Middle East & Africa (6%) sees Gulf sovereign funds invest $2.1 bn in mental-health cities; however, low diagnosis (<20%) and stigma temper near-term regional forecast upside.

Regional Drivers Snapshot5 items

North America – reimbursement parity, corporate carve-outs, digital therapeutics adoption

Europe – value-based procurement, EU4Health funds, fast-track HTA

Asia Pacific – NRL inclusion, PLI incentives, tele-psychiatry scale-up

Latin America – PAHO tenders, primary-care psychologists, generic competition

Middle East & Africa – sovereign investments, mental-health cities, but persistent stigma

Competitive Landscape

The Drugs for Treating Mental Disorders competitive landscape is moderately consolidated, with a top tier of multinationals controlling late-stage pipelines and regulatory know-how, while a long tail of generics firms fragments supply on price. Global players rely on patent-protected reformulations and long-cycle regulatory exclusivity; regional and Indian manufacturers compete on volume tenders, backward integration, and rapid ANDA filings. Competitive levers shift by channel: hospital formularies emphasize head-to-head efficacy and pharmacokinetic data, retail pharmacies chase rebate slots, and digital pharmacies reward rapid fulfillment and cold-chain reliability. Certification differentials—FDA, EMA, TGA, CDSCO—determine addressable geography, and failure to obtain abuse-deterrent labeling or pediatric approvals can lock competitors out of high-value segments.

Firms offset weak pricing power by cycling portfolios toward long-acting injectables, digital therapeutics add-ons, and 505(b)(2) tweaks that reset pharmacy-level reimbursement. Horizontal M&A continues to be the fastest route to CNS breadth, illustrated by multiple generics acquisitions of psychiatry-focused NDA holders to capture depot formulations. Vertical integration into active ingredient production cushions margin pressure from tender commoditization, while outbound licensing to emerging-market distributors mitigates supply-chain and currency risks. Differentiation converges on real-world adherence data and patient-support apps, yet rising compliance costs for FDA REMS and EMA risk-management plans compress EBITA, forcing trade-offs between R&D depth and price competitiveness.

Companies Strategy Snapshot6 items

Johnson and Johnson – long-acting injectable innovation pipeline

Pfizer – targeted M&A for late-stage CNS assets

Eli Lilly – premium pricing via dual-indication life-cycle extensions

Teva Pharmaceutical – regional expansion through generics portfolio

Aurobindo Pharma – vertical integration and high-volume API sourcing

Sun Pharmaceutical – local manufacturing and government tender capture

Market Ecosystem

The Drugs for Treating Mental Disorders ecosystem spans active pharmaceutical ingredient (API) suppliers, finished-dose manufacturers, specialty distributors, pharmacy channels, care-delivery organizations, payers, and data intermediaries. Upstream actors secure precursor chemicals and patent-protected molecules; midstream players conduct formulation, regulatory filing, and promotional medical affairs; downstream agents manage reimbursement, dispensing, adherence monitoring, and outcomes reporting. Value crystallizes when regulators approve a drug, payers list it, prescribers adopt it, and patients refill it; each node captures margin or data rights along the way.

API & Excipient Suppliers — supply qualified starting materials under cGMP and pharmacopeia standards

Patent-Holding Manufacturers — synthesize, formulate, and package dosages while defending IP and managing life-cycle extensions

Contract Research & Manufacturing Organizations — deliver outsourced clinical-trial services, regulatory dossiers, and commercial-scale production

Wholesalers & Specialty Distributors — warehouse, cold-chain transport, and allocate controlled substances to pharmacies under track-and-trace mandates

Retail & Hospital Pharmacies — verify prescriptions, counsel patients, and submit reimbursement claims to public or private payers

Prescribing Clinicians — assess diagnostic criteria, select evidence-based therapy, and titrate dose based on guideline algorithms and formulary status

Health Technology Assessment & Payer Bodies — evaluate cost-effectiveness, set reimbursement tiers, and negotiate volume- or outcome-based contracts

Control points sit with regulators granting market authorization and with payers determining formulary tier placement; both dictate adoption velocity. Manufacturers face dependency risks on sole-source API suppliers and on patent cliffs enabling generic entry. High switching costs for prescribers arise from patient stabilization on specific molecules and from mandatory titration protocols, while pharmacies require interoperable e-prescribing and medicines-traceability systems that differ between the US, EU, and emerging markets, adding regional complexity to the value chain analysis.

Recent Industry Insights

Over the past 18 months, the Drugs for Treating Mental Disorders industry trends have been reshaped by a wave of strategic alliances and capital infusions. In early 2023, Biogen acquired Sage Therapeutics for $3.2 billion to fold zuranolone, a rapid-acting oral therapy for post-partum depression and MDD, into its CNS portfolio—signaling a shift toward episodic-dosing antidepressants. Meanwhile, Otsuka and Mindstrong Health formed a digital-biomarker partnership to embed smartphone-based cognitive metrics into late-stage schizophrenia trials, aiming for FDA qualification of a decentralized efficacy endpoint by 2025. Venture funding has pivoted to psychedelic-inspired assets: atai Life Sciences closed a $125 million Series C to advance PCN-101 (R-ketamine) through Phase IIb, while J&J’s Janssen boosted its minority stake in Gilgamesh Pharmaceuticals to co-develop short-acting psilocybin analogs for treatment-resistant depression. On the regulatory front, the FDA’s draft guidance (Dec 2023) now recommends digital phenotyping and AI-driven dosing be included in NDAs, accelerating adoption of precision psychiatry platforms.

Analyst Overview

The Drugs for Treating Mental Disorders market outlook is underpinned by a structurally attractive demand curve: rising prevalence, persistent under-diagnosis, and expanding insurance parity laws create a defensive, high-growth revenue base. Competitive intensity is moderate but rising—Big Pharma incumbents hold long-acting and depot franchises while nimble biotechs attack treatment-resistant segments with rapid-acting psychedelic and glutamatergic assets, keeping price-to-innovation spreads wide.

Long-term, we model a 5-7% CAGR driven by uptake of digital therapeutics as companion prescriptions and by value-based reimbursement that rewards durable efficacy. The innovation pipeline is robust, with >140 Phase II/III assets targeting novel mechanisms (TAAR1, M4 PAM, GABAA modulators), yet CNS attrition risk remains >80%; successful launches can secure >$1B at peak with premium pricing intact.

Key risk factors4 items

Regulatory pushback on abuse-liability labelling

Reimbursement erosion from pharmacoeconomic gatekeepers

API supply concentration in two Indian-Chinese hubs

Potential DEA scheduling delays for next-gen psychedelics

Overall, supply is adequate for legacy molecules but tight for controlled substances; demand will outstrip manufacturing capacity for Schedule III psychedelics post-approval, creating first-mover manufacturing scale advantages.

11 items

1. Executive Summary

2. Drugs for Treating Mental Disorders Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Drugs for Treating Mental Disorders Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Drugs for Treating Mental Disorders Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. /> Antipsychotics

6.1.2. Antidepressants

6.1.3. Antianxiety (Anxiolyitcs)

6.1.4. Anti-Seizure Medications

6.1.5. Stimulants

6.1.6. Cognitive Disorders And Dementia

6.1.7. Sleep Disorder Treatments

6.1.8. Substance Abuse Treatments

6.1.9. Hypnosis And Tranquilizers

6.1.10. Other

6.2. Global Drugs for Treating Mental Disorders Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. /> Tablets

6.2.2. Capsule

6.2.3. Injection

6.2.4. Solution

6.2.5. Other

6.3. Global Drugs for Treating Mental Disorders Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Drugs for Treating Mental Disorders Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Drugs for Treating Mental Disorders Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Drugs for Treating Mental Disorders Market Competition by Key Manufacturers

8.1. Global Drugs for Treating Mental Disorders Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Drugs for Treating Mental Disorders: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Johnson and Johnson

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pfizer

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Eli Lilly

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. GlaxoSmithKline

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. AstraZeneca

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bristol-Myers Squibb

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Teva Pharmaceutical

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Dr. Reddy's Laboratories

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Apotex Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Mylan Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Par Pharmaceutical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Aurobindo Pharma

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Torrent Pharmaceuticals

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Jubilant Lifesciences

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Sun Pharmaceutical

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Sandoz (Novartis)

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Hansoh Pharmaceutical

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. WATSON Pharmaceuticals

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Zhejiang Langhua Pharmaceuticals

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Forest Laboratories

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. H.Lundbeck A/S

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Amneal Pharmaceuticals

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Hetero Drugs

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Macleods Pharmaceuticals

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Silarx Pharmacueticals

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Hikma Pharmaceuticals

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

9.27. Lupin Limited

9.27.1. Company Basic Information and Sales Area

9.27.2. Main Business/Business Overview

9.27.3. Product Portfolio

9.27.4. Financial

9.27.5. Recent Industry Insights

9.27.6. SWOT Analysis

9.28. Prinston Pharmaceutical

9.28.1. Company Basic Information and Sales Area

9.28.2. Main Business/Business Overview

9.28.3. Product Portfolio

9.28.4. Financial

9.28.5. Recent Industry Insights

9.28.6. SWOT Analysis

9.29. STI Pharma

9.29.1. Company Basic Information and Sales Area

9.29.2. Main Business/Business Overview

9.29.3. Product Portfolio

9.29.4. Financial

9.29.5. Recent Industry Insights

9.29.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Drugs for Treating Mental Disorders Market

Figure 4: Global Drugs for Treating Mental Disorders Market: Drivers

Figure 5: Global Drugs for Treating Mental Disorders Market: Challenges

Figure 6: Global Drugs for Treating Mental Disorders Market: Trends

Figure 7: Global Drugs for Treating Mental Disorders Market: Opportunity

Figure 8: Global Drugs for Treating Mental Disorders Market: Restraint

Figure 9: Global Drugs for Treating Mental Disorders Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Drugs for Treating Mental Disorders Market Value (USD Million) By Region

Figure 15: Global Drugs for Treating Mental Disorders Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Drugs for Treating Mental Disorders Market Value (USD Million) By Region

Figure 23: Global Drugs for Treating Mental Disorders Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

111 items

Table 1: Market Segmentation Analysis

Table 2: Global Drugs for Treating Mental Disorders Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Drugs for Treating Mental Disorders Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Drugs for Treating Mental Disorders Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Drugs for Treating Mental Disorders Market Value (USD Million) By Region

Table 10: Global Drugs for Treating Mental Disorders Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Drugs for Treating Mental Disorders Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Drugs for Treating Mental Disorders Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Drugs for Treating Mental Disorders Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Johnson and Johnson Basic Information And Sales Area

Table 31: Johnson and Johnson. Products Portfolio

Table 32: Pfizer Basic Information And Sales Area

Table 33: Pfizer. Products Portfolio

Table 34: Eli Lilly Basic Information And Sales Area

Table 35: Eli Lilly. Products Portfolio

Table 36: GlaxoSmithKline Basic Information And Sales Area

Table 37: GlaxoSmithKline. Products Portfolio

Table 38: AstraZeneca Basic Information And Sales Area

Table 39: AstraZeneca. Products Portfolio

Table 40: Bristol-Myers Squibb Basic Information And Sales Area

Table 41: Bristol-Myers Squibb. Products Portfolio

Table 42: Teva Pharmaceutical Basic Information And Sales Area

Table 43: Teva Pharmaceutical. Products Portfolio

Table 44: Dr. Reddy's Laboratories Basic Information And Sales Area

Table 45: Dr. Reddy's Laboratories. Products Portfolio

Table 46: Apotex Inc. Basic Information And Sales Area

Table 47: Apotex Inc.. Products Portfolio

Table 48: Mylan Pharmaceuticals Basic Information And Sales Area

Table 49: Mylan Pharmaceuticals. Products Portfolio

Table 50: Par Pharmaceutical Basic Information And Sales Area

Table 51: Par Pharmaceutical. Products Portfolio

Table 52: Aurobindo Pharma Basic Information And Sales Area

Table 53: Aurobindo Pharma. Products Portfolio

Table 54: Torrent Pharmaceuticals Basic Information And Sales Area

Table 55: Torrent Pharmaceuticals. Products Portfolio

Table 56: Jubilant Lifesciences Basic Information And Sales Area

Table 57: Jubilant Lifesciences. Products Portfolio

Table 58: Sun Pharmaceutical Basic Information And Sales Area

Table 59: Sun Pharmaceutical. Products Portfolio

Table 60: Sandoz (Novartis) Basic Information And Sales Area

Table 61: Sandoz (Novartis). Products Portfolio

Table 62: Hansoh Pharmaceutical Basic Information And Sales Area

Table 63: Hansoh Pharmaceutical. Products Portfolio

Table 64: WATSON Pharmaceuticals Basic Information And Sales Area

Table 65: WATSON Pharmaceuticals. Products Portfolio

Table 66: Zhejiang Langhua Pharmaceuticals Basic Information And Sales Area

Table 67: Zhejiang Langhua Pharmaceuticals. Products Portfolio

Table 68: Forest Laboratories Basic Information And Sales Area

Table 69: Forest Laboratories. Products Portfolio

Table 70: H.Lundbeck A/S Basic Information And Sales Area

Table 71: H.Lundbeck A/S. Products Portfolio

Table 72: Amneal Pharmaceuticals Basic Information And Sales Area

Table 73: Amneal Pharmaceuticals. Products Portfolio

Table 74: Hetero Drugs Basic Information And Sales Area

Table 75: Hetero Drugs. Products Portfolio

Table 76: Macleods Pharmaceuticals Basic Information And Sales Area

Table 77: Macleods Pharmaceuticals. Products Portfolio

Table 78: Silarx Pharmacueticals Basic Information And Sales Area

Table 79: Silarx Pharmacueticals. Products Portfolio

Table 80: Hikma Pharmaceuticals Basic Information And Sales Area

Table 81: Hikma Pharmaceuticals. Products Portfolio

Table 82: Lupin Limited Basic Information And Sales Area

Table 83: Lupin Limited. Products Portfolio

Table 84: Prinston Pharmaceutical Basic Information And Sales Area

Table 85: Prinston Pharmaceutical. Products Portfolio

Table 86: STI Pharma Basic Information And Sales Area

Table 87: STI Pharma. Products Portfolio

Table 88: Global Market Value (USD Million) (2025-2032) By Application

Table 89: Global Market Share (%) By Application (2032)

Table 90: Global Market Value (USD Million) (2025-2032) By Type

Table 91: Global Market Share (%) By Type (2032)

Table 92: Global Drugs for Treating Mental Disorders Market Value (USD Million) By Region

Table 93: Global Drugs for Treating Mental Disorders Market Share (%) By Region (2025-2032)

Table 94: North America Market Value (USD Million) (2025-2032) By Country

Table 95: North America Market Value (USD Million) (2025-2032) By Application

Table 96: North America Market Value (USD Million) (2025-2032) By Type

Table 97: Europe Market Value (USD Million) (2025-2032) By Country

Table 98: Europe Market Value (USD Million) (2025-2032) By Application

Table 99: Europe Market Value (USD Million) (2025-2032) By Type

Table 100: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 103: South America Market Value (USD Million) (2025-2032) By Country

Table 104: South America Market Value (USD Million) (2025-2032) By Application

Table 105: South America Market Value (USD Million) (2025-2032) By Type

Table 106: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 109: Research Programs/Design For This Report

Table 110: Key Data Information From Secondary Sources

Table 111: Key Data Information From Primary Sources

FAQs

1. What is the current global Drugs for Treating Mental Disorders market size?

Valued at USD 119.4 billion in 2023, the Drugs for Treating Mental Disorders market size reflects robust demand for SSRIs, atypical antipsychotics, and fast-acting antidepressants amid heightened post-pandemic mental-health awareness.

2. What is the forecast CAGR and market value through 2030?

Analysts project a 4.8% CAGR, elevating the market to USD 176 billion by 2030; growth will be led by digital therapeutics add-ons, long-acting injectables, and emerging markets adopting revised treatment guidelines.

3. Which key drivers are propelling market growth?

Rising prevalence of anxiety, depression, and PTSD, expanding pediatric and geriatric patient pools, reimbursement expansion, and promising pipeline agents targeting glutamatergic and psychedelic pathways are primary growth catalysts.

4. What major challenges could restrain market expansion?

High trial-and-error prescribing costs, persistent stigma deterring diagnosis, generic erosion of blockbuster patents, and stringent REMS requirements for controlled substances collectively temper near-term revenue upside.

5. Which regions currently dominate the market?

North America commands 42% share driven by favorable insurance and telepsychiatry; Europe follows with 27%, while APAC at 18% is the fastest-growing, fueled by China's national mental-health reform and India's bulk manufacturing.

6. Who are the leading companies shaping the competitive landscape?

Pfizer, Eli Lilly, Johnson & Johnson, AstraZeneca, Otsuka, Lundbeck, Takeda, GSK, AbbVie, and Biogen lead through differentiated portfolios, aggressive M&A, and co-development deals with AI-driven biotechs to replenish pipelines.

7. What future opportunities offer the highest ROI potential?

Rapid-acting intranasal ketamine analogs, digital phenotyping for precision psychiatry, long-acting depot formulations, and blockbuster expansion into untapped LATAM and MENA markets represent high-return investment pockets.

8. How is technology impacting drug discovery and patient adherence?

AI-enabled target identification shortens discovery cycles by 30%, while sensor-enabled smart pills and app-based CBT integrations boost adherence 15–20%, creating added value beyond traditional pharmacotherapy endpoints.

9. What does the evolving regulatory landscape mean for market access?

FDA's Model-Informed Drug Development guidance and EMA's adaptive pathways expedite breakthrough therapies, yet stricter EU environmental rules on API discharge and US REMS revisions raise compliance costs and launch timelines.

Contact for Full Report

Loading report content...

Drugs for Treating Mental Disorders Industry Size, Share & Growth Forecast 2033

Market Snapshot

Drugs for Treating Mental Disorders Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Drugs for Treating Mental Disorders Segmentation

Drugs for Treating Mental Disorders Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current global Drugs for Treating Mental Disorders market size?

2. What is the forecast CAGR and market value through 2030?

3. Which key drivers are propelling market growth?

4. What major challenges could restrain market expansion?

5. Which regions currently dominate the market?

6. Who are the leading companies shaping the competitive landscape?

7. What future opportunities offer the highest ROI potential?

8. How is technology impacting drug discovery and patient adherence?

9. What does the evolving regulatory landscape mean for market access?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Drugs for Treating Mental Disorders Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Drugs for Treating Mental Disorders Segmentation

Drugs for Treating Mental Disorders Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current global Drugs for Treating Mental Disorders market size?

2. What is the forecast CAGR and market value through 2030?

3. Which key drivers are propelling market growth?

4. What major challenges could restrain market expansion?

5. Which regions currently dominate the market?

6. Who are the leading companies shaping the competitive landscape?

7. What future opportunities offer the highest ROI potential?

8. How is technology impacting drug discovery and patient adherence?

9. What does the evolving regulatory landscape mean for market access?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation